

NeuroScientific

ASX:NSB

For personal use only

Patented Stem Cell Solutions for Complex Auto-Immune Disorders & Unmet Needs

Nathan Smith | Chief Executive Officer

JMM Investor Lunch | February 2026

Disclaimers

NeuroScientific

Presentation Information

This presentation has been prepared by NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in NSB, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of NSB and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. NSB is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of NSB securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of NSB, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. The information presented in this presentation is subject to change without notice and NSB does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward Looking Statements

This presentation contains certain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of NSB to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which NSB will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward-looking statements or other forecast. To the full extent permitted by law, NSB and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Investment Highlights

NeuroScientific

01

Robust Profile & Strong Balance Sheet

\$43.2M market cap¹ with \$6.4M in cash.²

Strong leadership team, and a world-class Scientific Advisory Board of experts.

02

Patented StemSmart™ Tech Platform

Proprietary manufacturing processes for differentiated MSC therapeutics with a global IP position.

03

Proven Clinical Safety & Efficacy

Strong safety profile and 78% overall response in refractory Crohn's trial.³

Clinical response in Special Access Program for Fistulising Crohn's disease.

04

Secure Supply Chain & Commercialisation Path

Expanded manufacturing capacity through technology transfer and scale-up with GMP-licensed cell therapy manufacturer, Q-Gen.

1. As at 11 February 2026
2. ASX Announcement (30 January 2026) – "December 2025 Quarterly Activities Report (Q2 FY26)"
3. ASX Announcement (16 April 2025) – "NeuroScientific to Acquire Leading Stem Cell Technology"

Company Overview

NeuroScientific

Corporate Share Information

As at 11 February 2026


SHARE PRICE	A\$0.13
MARKET CAPITALISATION	~A\$43.2 million

Capital Structure & Cash On Hand

	ORDINARY SHARES	PERFORMANCE SHARES	OPTIONS
CAPITAL	332.6 million	57.1 million	48.25 million
CASH	~\$6.4 million (31/12/25)		

Share Price

As at 11 February 2026



Strength in Leadership & Advisory



ROB MCKENZIE
LL.B; B.Juris, FAICD
NON-EXECUTIVE CHAIRMAN

- Lawyer with over 35 years' experience in corporate and commercial transactions, restructuring and dispute resolution
- Advised on M&A; IPOs; corporate structure; corporate governance; board and compliance, and financial structuring
- Chairman of the Perron Institute and was previously on the Takeovers Panel



DR ANTON UVAROV
PhD, MBA
NON-EXECUTIVE DIRECTOR

- Significant healthcare industry experience with a focus on neuroscience
- Former equities analyst for Citigroup and Co-Founder of several publicly-listed Australian companies (e.g., Dimerrix [ASX:DXB], Actinogen Medical [ASX:ACW], BlinkLab [ASX:BB1])
- Currently Executive Director at BlinkLab Limited (ASX:BB1)



PAUL FRY
BBus
NON-EXECUTIVE DIRECTOR

- Former Partner of Ernst & Young and PwC in Australia and Canada
- Expertise surrounding public markets, capital raisings, governance, risk management, and corporate transactions
- Consults to companies across various industries and has been involved with a number of publicly-listed ASX entities



CLARKE BARLOW
BCom, MAICD
NON-EXECUTIVE DIRECTOR

- Financial Advisor and Capital Markets Specialist with over 20 years' experience in financial services across Australia and the UK
- Extensive experience providing corporate advisory services for ASX-listed companies across various industries, with a focus on growth opportunities in biotechnology, technology, industrial, and resources.



NATHAN SMITH
BSc
CHIEF EXECUTIVE OFFICER

- Over 25 years' experience across biologics and cell & gene therapies
- Formerly at GlaxoSmithKline, Sanofi Genzyme, Mesoblast, BioReliance, and most recently Cell Therapies Pty Ltd leading business development



DR MARIAN STURM
FFSc (RCPA), PhD, MSc, BSc Hons
CHIEF SCIENTIFIC OFFICER

- Expert with 40 years' experience in research, operational and clinical development of cellular treatments
- Manufacturing of therapeutic goods for over 20 years, and was a member for TGA Advisory Committee on Biologics (2012-2022)



PROF CATHERINE COLE
MBBS, FRACP, FRCPA
CHIEF MEDICAL OFFICER

- 35 years experience in clinical paediatric haematology, oncology, clinical trials & stem cell transplantation
- Served on TGA Advisory Committee for Prescription Medicines & Pharmaceutical Benefits Advisory Committee (PBAC)

New Clinical & Scientific Advisory Board ¹

NeuroScientific



PROF CATHERINE COLE
MBBS, FRACP, FRCPA
CHIEF MEDICAL OFFICER

- 35 years experience in clinical paediatric haematology, oncology, clinical trials & stem cell transplantation
- Served on TGA Advisory Committee for Prescription Medicines & Pharmaceutical Benefits Advisory Committee (PBAC)



DR MARIAN STURM
FFSc (RCPA), PhD, MSc, BSc Hons
CHIEF SCIENTIFIC OFFICER

- Expert with 40 years' experience in research, operational and clinical development of cellular treatments
- Manufacturing of therapeutic goods for over 20 years, and was a member for TGA Advisory Committee on Biologics (2012-2022)



DR ASHLEY IRISH
MBBS, FRACP
ADVISORY BOARD MEMBER

- Clinical Professor at the University of Western Australia and Renal Transplant Lead Clinician at Fiona Stanley Hospital
- Expertise in renal transplantation, dialysis, chronic kidney and cardiovascular disease
- Leads the West Australian Country Health Service (WACHS) Renal Program and provides specialist services across major WA hospitals



DR LENA THIN
MClinRes, MBBS
ADVISORY BOARD MEMBER

- Consultant Gastroenterologist at Fiona Stanley Hospital with a focus on Inflammatory Bowel Disease (IBD)
- Principal Investigator for the IBD Research Unit, leading multiple international clinical trials
- Executive member of the Australian and New Zealand IBD Research Consortium and Adjunct Senior Clinical Lecturer at UWA



DR MICHAEL MUSK
MBBS, FRACP
ADVISORY BOARD MEMBER

- Respiratory Physician and Medical Director at Fiona Stanley Hospital, leading the Advanced Lung Disease Unit
- Specialist in lung transplantation, interstitial lung disease, and pulmonary vascular disease
- Principal Investigator for numerous respiratory trials and member of the Transplant Society of Australia and New Zealand



PROF YUBEN MOODLEY
MBBS, FRACP, MD, PhD
ADVISORY BOARD MEMBER

- Consultant Respiratory Physician at Fiona Stanley Hospital and Professor of Respiratory Medicine at UWA
- Co-Deputy Director of the Institute for Respiratory Health and Research Leader of the Cell Biology Group
- Expertise in pulmonary fibrosis, COPD, and lung cell biology; member of scientific advisory boards for Roche and Boehringer Ingelheim

1. ASX Announcement (6 November 2025) – "Neuroscientific Appoints Clinical & Scientific Advisory Board"

Introducing StemSmart™

NeuroScientific

The StemSmart™ MSC product is potent, efficacious and safe¹



StemSmart™ is a global patented technology resulting in activated MSC, differentiated from others in product class



High-quality product is manufactured under StemSmart™ methodology in TGA-accredited facilities



Large number of patients treated with no serious adverse safety events reported¹



StemSmart™ performs best in diseases with HIGH to SEVERE inflammation, where conventional treatments have failed

Initial Target Indications

Refractory Crohn's Disease (Life-Threatening)

- Unresponsive to conventional therapies
- ~30% patients become refractory
- Surgery is often the only option

Fistulising Crohn's Disease (Fistulas)

- Sores or ulcers in gastrointestinal tract
- About 30% of Crohn's patients will develop fistulas
- Unresolved chronic inflammation



6-8 Million

People living with Crohn's disease globally

StemSmart™

1. ASX Announcement (16 April 2025) – "Neuroscientific to Acquire Leading Stem Cell Technology"

Special Access Program – StemSmart™

NeuroScientific

Special Access Scheme (SAS) – Demonstrating a “Clinical Response” and the Path to Phase 2

What has been achieved?

NSB is already treating patients with Fistulising Crohn’s Disease under the TGA’s SAS Category B pathway, gathering real-world data to inform its planned Phase II Clinical Trial.

Initial patients were approved¹ and the first four (4) patients commenced treatment² with StemSmart™ for Fistulising Crohn’s Disease.

Demonstrated a successful “**clinical response**” for three (3) patients in SAS program,³ defined as:

- Closure of ≥50% of fistula openings; or
- Decrease in fistula discharge of ≥50%

Fourth patient showing partial response and requires further assessment.

What does this mean for NSB?



Confirms that StemSmart™ shows a meaningful benefit to some fistulising Crohn’s patients in a real-world setting, reinforcing the previous Phase 2 results in the broader refractory Crohn’s population.



Provides early validation of the StemSmart™ platform in a patient group with unmet medical needs, and for a condition that faces limited and ineffective treatment options.



De-risks development and clinical trial process by generating real-world efficacy and safety insights, patient responses to treatment, and best practice for clinicians.



SAS data directly informs the design for NeuroScientific’s planned Phase 2 Clinical Trials taking place in CY2026.

StemSmart™

1. ASX Announcement (7 October 2025) – “First Patients Approved for Special Access Program”

2. ASX Announcement (11 November 2025) – “NSB Progresses through Clinical Development Program with Fourth Patient Commencing Treatment Under Special Access Scheme”

3. ASX Announcement (13 January 2026) – “Successful Clinical Results Achieved under Special Access Program”

Product Pipeline & Market Size

NeuroScientific

Key Clinical Targets (StemSmart™ Addressable Markets)

		Global Market	Forecast Increase in Market
	Crohn's Disease	- Need for more effective treatments with less side effects - Require additional treatment option for patients who have failed all other medical therapies	US\$13.8 billion By 2026¹ Increase from US\$9.0 billion in 2016 53% from 2016
	Kidney Transplant	- Need rescue therapies for acute renal rejection - Minimise rejection risk, while reducing toxicity - Need to improve long term patient graft function and patient survival	US\$7.2 billion By 2030² (Organ transplant immuno-suppressants) Increase from US\$5.5 billion in 2024 31% from 2014
	Lung Disorders	- No long-term effective treatment for COPD – results in airflow obstruction (obstructive bronchiolitis and emphysema) - Lung Transplant Rejection - Current treatments cumbersome, ineffective, terminal disease	US\$33 billion By 2034³ Increase from US\$20 billion in 2024 65% from 2024
	GvHD	- Patients may develop a severe and life-threatening condition after a bone marrow transplant - Currently low rate of survival in severe refractory GVHD	US\$5.31 billion in 2032⁴ Increase from US\$2.55 billion in 2023 208% from 2023

1. [Crohn's Disease: Dynamic Market Forecast to 2026](#)
2. [Grand View Research - Organ Transplant Immunosuppressant Drugs Market Size](#)
3. [PharmaPoint: Chronic Obstructive Pulmonary Disease – Global Drug Forecast Market Analysis to 2025 – *for organ transplant immuno-suppressants](#)
4. [Global Graft versus Host Disease \(GVHD\) Market 2019-2029](#)

Key Milestones

NeuroScientific


Crohn's Disease - StemSmart™

- SAS Program – Fistulising Crohn's Disease
(Commenced June 2025)
- Phase 2 Start-up Activities
- Phase 2 Trial (Australia & US)
- Partnership Finalisation
- Phase 3 Start-up Activities
- Phase 3 Trial (Global)
- NDA submission

2nd Indication

- Phase 1/2 Start-up Activities
- Phase 1/2 Trial (Australia)

ASX Announcement – “Successful Clinical Results Achieved Under Special Access Program”
(13 January 2026)




Securing the StemSmart™ Supply Chain

NeuroScientific

Partnership with Q-Gen Cell Therapeutics¹

- > Tech transfer has been initiated for NSB's patented manufacturing process with targeting Phase 2 clinical trial supply by 2H CY2026.
- > Q-Gen has a 13-cleanroom facility that has been licensed by the TGA for manufacturing, testing and release for supply of clinical products.
- > With over 25 years' experience in cell therapy manufacturing supporting industry, Q-Gen has the capacity and capability to support NSB's clinical and commercial objectives.

Patented StemSmart™ Manufacturing Process



1. ASX announcement 31 July 2025 - “NeuroScientific Partners with Leading Biologic Manufacturer”

The Vision for Stem Cell Therapies...

NeuroScientific


For personal use only



Global Crohn's Solution for Unmet Medical Need



Over 6 Million people are living with Crohn's globally (over 1 million in US alone) with over 30% not responding to conventional treatment including blockbuster biologics.



Patented Platform

StemSmart™



Significant potential across use cases, with a proprietary Mesenchymal Stem Cell (MSC) technology that enhances safety, efficacy, and manufacturing consistency.



Programs Underway & Demonstrated Potential



Special Access Program for Fistulising Crohn's Disease underway and demonstrated a "Clinical Response", with previous Phase 2 trial achieving 78% overall response rate in Refractory Crohn's¹, as well as future global Phase 2 trial planned for late 2026.



Expansion to High-Value Therapeutic Indications



MSC therapy validated by US FDA approval² and targeting large, high-growth markets such as Crohn's Disease, Kidney Transplant, Lung Disorders, and more – a significant total market across all indications (US \$35 — 40 billion).

What's Next?

Phase 2 is in sight...

The Crohn's Special Access Program is underway, paving the way for a global Phase 2 trial in 2026.

Indications Expanding...

StemSmart™ is applicable to kidney transplant, GvHD, and lung disorders, and more – unlocking broad therapeutic markets.

Manufacturing Secured

GMP process transfer to Q-Gen enables scaling for clinical trials and future commercialisation.

1. ASX Announcement (16 April 2025) - "NeuroScientific to Acquire Leading Stem Cell Technology"
2. Mesoblast Limited ASX Announcement (19 December 2024) – "Mesoblast's Ryoncil® is the First U.S. FDA-approved Mesenchymal Stromal Cell (MSC) Therapy"

NeuroScientific

ASX:NSB

Contact

Nathan Smith

Chief Executive Officer

+61 477 738 404

nsmith@neuroscientific.com

Dr Anton Uvarov

Founding Non-Executive Director

+61 8 6268 2641

au@neuroscientific.com

For personal use only

NeuroScientific

ASX:NSB

Appendix

FY2026 - Announcements & News Flow

NeuroScientific

Key Announcements from Q1, Q2, and Q3 of FY2026

25/07/2025	Dr Catherine Cole Appointed as Chief Medical Officer	Dr Catherine Cole, esteemed clinician and regulatory expert, to guide MSC therapies
28/07/2025	Experienced Cell Therapy Executive Appointed CEO	Mr Nathan Smith, experienced cell and gene therapy leader, takes on role as CEO
31/07/2025	NeuroScientific Partners with Leading Biologic Manufacturer	Leading GMP-certified manufacturer and facilities, enhancing production capabilities
19/08/2025	Presentation - TechKnow Invest Roadshow Conference	Conference Presentation – TechKnow Invest (Hobart)
27/08/2025	Previous StemSmart Studies Support Renal Transplantation	Highly-encouraging safety and efficacy demonstrated in early StemSmart™ studies
28/08/2025	2025 Annual Report & Appendix 4E	
28/08/2025	Appendix 4G & Corporate Governance Statement	
16/09/2025	Date of AGM & Closing Date for Director Nominations	
07/10/2025	First Patients Approved for Special Access Program	TGA approval of initial patients in first cohort of Crohn's Disease special access program
21/10/2025	AusBiotech Presentation	Conference Presentation – AusBiotech Invest (Melbourne)
06/11/2025	Clinical & Scientific Advisory Board Appointed	Expert Advisory Board to guide key appointments, manufacturing, and clinical progress
11/11/2025	Fourth Patient Commences StemSmart MSC Treatment	In pursuit of real-world data to support upcoming Phase 2 clinical trial
13/03/2026	Successful Clinical Results Under Special Access	Three initial patients demonstrating a “Clinical Response” to StemSmart™ Therapeutic under SAS